^
Association details:
| Biomarker: | ER positive + ESR1 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | GDC-0927 (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
Published date:
06/01/2023
Excerpt:
This phase I dose-escalation multicenter study enrolled postmenopausal women with ER+/HER2- metastatic breast cancer to determine the safety, pharmacokinetics, and recommended phase II dose of GDC-0927....Twelve patients (29%) achieved clinical benefit; 17 patients (41%) showed a confirmed best overall response of stable disease….There was evidence of target engagement and preliminary evidence of anti-tumor activity in heavily pretreated patients with advanced/metastatic ER+/HER2- breast cancer with and without ESR1 mutations.
DOI:
10.1158/1078-0432.CCR-23-0011
